AU2019241765B2 - Heterocyclic compound and use thereof - Google Patents

Heterocyclic compound and use thereof Download PDF

Info

Publication number
AU2019241765B2
AU2019241765B2 AU2019241765A AU2019241765A AU2019241765B2 AU 2019241765 B2 AU2019241765 B2 AU 2019241765B2 AU 2019241765 A AU2019241765 A AU 2019241765A AU 2019241765 A AU2019241765 A AU 2019241765A AU 2019241765 B2 AU2019241765 B2 AU 2019241765B2
Authority
AU
Australia
Prior art keywords
methyl
difluoromethoxy
fluoro
benzamide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019241765A
Other languages
English (en)
Other versions
AU2019241765A1 (en
AU2019241765A8 (en
Inventor
Jumpei AIDA
Masaki DAINI
Mitsuhiro Ito
Kouichi Iwanaga
Hiroyuki Kakei
Makoto Kamata
Taku Kamei
Shigemitsu Matsumoto
Satoshi Mikami
Shinji Morimoto
Masataka Murakami
Minoru Nakamura
Shinji Nakamura
Yuya Oguro
Masaki Seto
Kazuaki Takami
Sachie TAKASHIMA
Taisuke Tawaraishi
Norihito Tokunaga
Yasufumi Wada
Takeshi Wakabayashi
Satoshi Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2019241765A1 publication Critical patent/AU2019241765A1/en
Publication of AU2019241765A8 publication Critical patent/AU2019241765A8/en
Application granted granted Critical
Publication of AU2019241765B2 publication Critical patent/AU2019241765B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019241765A 2018-03-28 2019-03-27 Heterocyclic compound and use thereof Active AU2019241765B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-062939 2018-03-28
JP2018062939 2018-03-28
PCT/JP2019/014901 WO2019189945A1 (en) 2018-03-28 2019-03-27 Heterocyclic compound and use thereof

Publications (3)

Publication Number Publication Date
AU2019241765A1 AU2019241765A1 (en) 2020-11-12
AU2019241765A8 AU2019241765A8 (en) 2021-02-18
AU2019241765B2 true AU2019241765B2 (en) 2022-07-07

Family

ID=66397395

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019241765A Active AU2019241765B2 (en) 2018-03-28 2019-03-27 Heterocyclic compound and use thereof

Country Status (17)

Country Link
US (2) US10807987B2 (enExample)
EP (1) EP3774800B1 (enExample)
JP (1) JP7279067B2 (enExample)
KR (1) KR20200136957A (enExample)
CN (1) CN111936495A (enExample)
AR (1) AR115020A1 (enExample)
AU (1) AU2019241765B2 (enExample)
BR (1) BR112020018238A2 (enExample)
CA (1) CA3100133A1 (enExample)
EA (1) EA202092294A1 (enExample)
ES (1) ES3006012T3 (enExample)
IL (1) IL276912A (enExample)
MA (1) MA52214A (enExample)
MX (1) MX2020010148A (enExample)
SG (1) SG11202008519RA (enExample)
TW (1) TW202003519A (enExample)
WO (1) WO2019189945A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3774800B1 (en) * 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016104434A1 (ja) * 2014-12-24 2016-06-30 武田薬品工業株式会社 複素環化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5252563A (en) * 1991-12-19 1993-10-12 G. D. Searle & Company 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury
JP3439551B2 (ja) * 1994-11-08 2003-08-25 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
EP1586584A1 (en) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
EP1390034A4 (en) * 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
JP2004161716A (ja) * 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Jnk阻害剤
CA2521907A1 (en) * 2003-04-10 2004-10-21 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
AU2010210426B2 (en) * 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
EP2694509B1 (en) * 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
JP6827757B2 (ja) 2016-10-11 2021-02-10 鬼怒川ゴム工業株式会社 ウエザーストリップ取付用クリップ
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3774800B1 (en) * 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
WO2020196828A1 (ja) 2019-03-28 2020-10-01 武田薬品工業株式会社 含窒素複素環化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016104434A1 (ja) * 2014-12-24 2016-06-30 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
US20190300536A1 (en) 2019-10-03
AU2019241765A1 (en) 2020-11-12
CN111936495A (zh) 2020-11-13
SG11202008519RA (en) 2020-10-29
EP3774800C0 (en) 2024-11-13
CA3100133A1 (en) 2019-10-03
EA202092294A1 (ru) 2021-01-15
AU2019241765A8 (en) 2021-02-18
IL276912A (en) 2020-10-29
EP3774800A1 (en) 2021-02-17
KR20200136957A (ko) 2020-12-08
ES3006012T3 (en) 2025-03-17
EP3774800B1 (en) 2024-11-13
JP7279067B2 (ja) 2023-05-22
US20210332053A1 (en) 2021-10-28
AR115020A1 (es) 2020-11-18
TW202003519A (zh) 2020-01-16
WO2019189945A8 (en) 2020-10-15
WO2019189945A1 (en) 2019-10-03
JP2021519294A (ja) 2021-08-10
BR112020018238A2 (pt) 2020-12-29
US11702419B2 (en) 2023-07-18
MX2020010148A (es) 2020-12-07
MA52214A (fr) 2021-04-21
US10807987B2 (en) 2020-10-20

Similar Documents

Publication Publication Date Title
US10208046B2 (en) Nitrogen-containing heterocyclic compound
US11702419B2 (en) Heterocyclic compound and use thereof
CA3071825A1 (en) Heterocyclic compound
US11713311B2 (en) Heterocyclic compound
US10548899B2 (en) Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
EP3313836A1 (en) 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
EP3239150B1 (en) Heterocyclic compound
EP3915638A1 (en) Heterocyclic compound and use thereof
EP4034257B1 (en) Heterocyclic compound and use thereof
EP4046688B1 (en) Heterocyclic compound
HK40059391A (en) Heterocyclic compound and use thereof
HK40077256B (en) Heterocyclic compound and use thereof
HK40077256A (en) Heterocyclic compound and use thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 45 , PAGE(S) 6445 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME TAKEDA PHARMACEUTICAL COMPANY LIMITED, APPLICATION NO. 2019241765, UNDER INID (72) CORRECT THE CO-INVENTOR TO IWANAGA, KOUICHI

FGA Letters patent sealed or granted (standard patent)